JULIO BELARMINO
BOBES GARCIA


AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublications in collaboration with researchers from AstraZeneca (United Kingdom) (5)
2010
-
Extended-release quetiapine fumarate (quetiapine XR): A once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and active-controlled study
International Journal of Neuropsychopharmacology, Vol. 13, Núm. 3, pp. 305-320
2008
-
Validity and reliability of the Spanish versions of the Bech-Rafaelsen's mania and melancholia scales for bipolar disorders
Acta Psychiatrica Scandinavica, Vol. 117, Núm. 3, pp. 207-215
2007
-
Sensitivity to change, discriminative performance, and cutoff criteria to define remission for embedded short scales of the Hamilton depression rating scale (HAMD)
Journal of Affective Disorders, Vol. 102, Núm. 1-3, pp. 93-99
-
The "Seroquel" Outcomes Study (SOS): Efficacy and tolerability of quetiapine in a long-term, naturalistic study of patients with schizophrenia
International Journal of Psychiatry in Clinical Practice, Vol. 11, Núm. 3, pp. 222-232
-
The sufficiency of the HAM-D6 as an outcome instrument in the acute therapy of antidepressants in the outpatient setting
International Journal of Psychiatry in Clinical Practice, Vol. 11, Núm. 2, pp. 146-150